Peptide Comparison
Semaglutide vs Dulaglutide
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
This combination is flagged
GLP-1 agonist + insulin or sulfonylureas: High risk per peptide research literature. Hypoglycemia risk: GLP-1 enhances glucose-dependent insulin secretion; stacking with exogenous insulin or secretagogues can drive severe lows.
Data-derived verdict
Semaglutide and Dulaglutide share the glp-1 class and carry roughly equivalent evidence (FDA-Approved / FDA-Approved). On the catalogued data layer Semaglutide has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Semaglutide's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: nausea. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| Semaglutide | Dulaglutide | |
|---|---|---|
| Class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Drug class | Metabolic & Weight | Metabolic & Weight |
| Mechanism | GLP-1R activation; delays gastric emptying; central appetite suppression; enhances glucose-dependent insulin secretion [1][2] | GLP-1 receptor agonist fused to human IgG4 Fc |
| Route | SC injection / Oral | SC injection |
| Half-life | ~7 days | ~5 days |
| Dosage (research) | 0.25 mg SC weekly (Wegovy/Ozempic label starting dose, escalate monthly to label max 2.4 mg weekly per STEP-1 protocol) [1][2][3]; oral 3 mg daily Rybelsus starting dose (target 14 mg daily) | 0.75 mg SC weekly (Trulicity label starting dose, escalate stepwise to 1.5, 3.0, then label max 4.5 mg weekly for additional glycemic control per AWARD trials) |
| Evidence tier | FDA-Approved | FDA-Approved |
| Research depth | 258 indexed | 258 indexed |
| Availability | Prescription | Prescription |
| Reported risks | Nausea; vomiting; constipation; pancreatitis; gallbladder disease; thyroid C-cell tumor warning [1][2] | Nausea; diarrhea; pancreatitis risk; thyroid C-cell tumor warning |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Semaglutide or Dulaglutide?
Semaglutide and Dulaglutide share the glp-1 class and carry roughly equivalent evidence (FDA-Approved / FDA-Approved). On the catalogued data layer Semaglutide has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Semaglutide's evidence base is currently denser.
What is the difference between Semaglutide and Dulaglutide?
Semaglutide is classed as GLP-1 receptor agonist; Dulaglutide is classed as GLP-1 receptor agonist. Reported mechanism: Semaglutide, GLP-1R activation; delays gastric emptying; central appetite suppression; enhances glucose-dependent insulin secretion; Dulaglutide, GLP-1 receptor agonist fused to human IgG4 Fc. Reported half-life: Semaglutide, ~7 days; Dulaglutide, ~5 days. Routes in published studies: Semaglutide, SC injection / Oral; Dulaglutide, SC injection.
Which has stronger evidence, Semaglutide or Dulaglutide?
Semaglutide and Dulaglutide sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Semaglutide is graded FDA-Approved, with 70 cited sources on its reference page and 258 indexed studies. Dulaglutide is graded FDA-Approved, with 38 cited sources on its reference page and 258 indexed studies.
Which is more accessible, Semaglutide or Dulaglutide?
Both Semaglutide and Dulaglutide are FDA-approved drugs. Catalog status: Semaglutide, Prescription; Dulaglutide, Prescription.
Are Semaglutide and Dulaglutide ever combined?
Semaglutide and Dulaglutide appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…